Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 6/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24180131 | 0.83 | PDE4A (0.44) | NPY1RNPY2RPDE4ACARM1PRMT1 | |
| SCHEMBL22957846 | 0.82 | NPY1R (0.70) | NPY1RNPY2RPDE4ARIPK1EPHX2 | |
| SCHEMBL22390612 | 0.81 | RIPK1 (0.58) | NPY1RNPY2RSLC6A2PDE4ARIPK1 | |
| SCHEMBL29786553 | 0.80 | CSNK2A1 (0.51) | NPY1RNPY2RSLC6A2PDE4ACARM1 | |
| SCHEMBL20472386 | 0.80 | CSNK2A1 (0.51) | NPY1RNPY2RSLC6A2PDE4ACARM1 | |
| SCHEMBL22391953 | 0.80 | RIPK1 (0.61) | SLC6A2RIPK1SLC6A4 | |
| SCHEMBL24180134 | 0.79 | PDE4A (0.47) | NPY1RNPY2RSLC6A2PDE4APDE4B | |
| SCHEMBL22957683 | 0.79 | SLC6A4 (0.54) | NPY1RNPY2RSLC6A2PDE4ACARM1 | |
| SCHEMBL22957878 | 0.79 | NPY1R (0.56) | NPY1RNPY2RPDE4ARIPK1EPHX2 | |
| SCHEMBL12775726 | 0.77 | KDM4E (0.45) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | RIPK1, RIPK4, RIPK3 | NPY1R 4215/4885NPY2R 4585/4885SLC6A2 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.